|Articles|December 13, 2013
The Utility of the BRCAvantage Test
Author(s)Sukumar Nagendran, MD
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
Advertisement
Clinical Pearls
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
- BRCAvantage was launched in mid-October
- The test is a comprehensive solution to help patients and healthcare providers make clinical decisions regarding the prognostic nature of their disease course and treatment interventions
- BRCAvantage includes a complete analysis of BRCA1 and BRCA2 as well as targeted tests for other specific gene mutations and family gene mutations
<<<
Advertisement
Related Articles
- Dato-DXd Shows Tolerability Vs Chemo in HER2- Metastatic Breast Cancer
September 16th 2025
- COCOON DM Reduces Skin AEs With Ami/Laz for NSCLC
September 15th 2025
- Reviewing Ribociclib's Role in HR+, HER2- Early Breast Cancer
September 10th 2025
- ABBV-706 Shows Durable Benefit in Relapsed SCLC
September 10th 2025
- GLSI-100 Gets FDA Fast Track Designation for Breast Cancer
September 10th 2025
- Firmonertinib Shows Efficacy, CNS Activity in EGFR+ NSCLC
September 10th 2025
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology
1
Dato-DXd Shows Tolerability Vs Chemo in HER2- Metastatic Breast Cancer
2
New Targets Emerge for Aggressive Small Cell Lung Cancer
3
Ligufalimab Earns FDA Orphan Drug Designation in AML
4
Clinical Factors and Transplantation Are Associated With PCL Prognosis
5